Highly purified cannabidiol ( <scp>CBD</scp> ) in <scp>CDKL5</scp> deficiency disorder ( <scp>CDD</scp> ): Open‐label prospective study
We studied nine girls with CDKL5 deficiency disorder who had frequent, hard-to-treat seizures. They received cannabidiol for up to 1 year, added to their usual medicines. Most children had fewer seizures in the first months of treatment. Some families also noticed better alertness, eye contact, movement, sleep, or constipation. Side effects were usually mild and manageable. Although seizure frequency often returned to baseline by the end of the study, most families chose to continue cannabidiol. Because this was a small study without a placebo group, these results are preliminary, and larger controlled trials are needed.
Authors
- Domenica Battaglia (ORCID: https://orcid.org/0000-0003-0491-4021)
- Elisa Musto (ORCID: https://orcid.org/0000-0002-3298-2390)
- Maria Luigia Gambardella (ORCID: https://orcid.org/0000-0002-4132-6221)
- Chiara Veredice (ORCID: https://orcid.org/0000-0003-2267-8077)
- Valentina Massaroni (ORCID: https://orcid.org/0000-0001-8222-4961)
- Marco Perulli (ORCID: https://orcid.org/0000-0003-3311-2765)
- Federica Ascione (ORCID: https://orcid.org/0000-0002-5998-4310)
- Maria Picilli
- Chiara Porto
- Alessia de Gioia
- Ilaria Contaldo
- Federica Ruggiero
- Michela Quintiliani
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Agostino Gemelli University Polyclinic (IT)
Publication Details
- Journal
- Epilepsia Open
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1002/epi4.70213
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00